Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01204671 · ClinicalTrials.gov registry record · Phase 3
Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A)
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,659
- Enrollment target
NCT01204671 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 4,659 participants.
The verdict
NCT01204671, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,659 participants
- Enrollment target
Study Summary
This study is designed to assess the safety and immunogenicity of a GSK Biologicals' investigational vaccine GSK2321138A in adults 18 years old and older. This study is also designed to assess the lot-to-lot consistency of vaccine GSK2321138A. The blinding will be double blind for all groups except for the GSK2604409A Group which will be open.
Interventions
- BIOLOGICAL Influenza vaccine GSK2321138A
- BIOLOGICAL FluarixTM
- BIOLOGICAL Influenza vaccine GSK2604409A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,659 participants |
| Start Date | 2010-10-04 |
| Est. Completion | 2011-06-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01204671
The ClinicalTrials.gov registry entry for NCT01204671 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 4,659 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Influenza vaccine GSK2321138A is the first listed.
NCT01204671 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01204671 about?
NCT01204671 is a clinical study titled "Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A)". This study is designed to assess the safety and immunogenicity of a GSK Biologicals' investigational vaccine GSK2321138A in adults 18 years old and older. This study is also designed to assess the lot-to-lot consistency of vaccine GSK2321138A. The blinding will be double blind for all groups except ...
What is the current status of trial NCT01204671?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,659 participants. The study started on 2010-10-04. Estimated completion is 2011-06-06.
What interventions are being tested in trial NCT01204671?
The interventions under investigation include: Influenza vaccine GSK2321138A (BIOLOGICAL), FluarixTM (BIOLOGICAL), Influenza vaccine GSK2604409A (BIOLOGICAL).
Who is sponsoring clinical trial NCT01204671?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.